First-in-class therapy repairs DNA damage in Alzheimer's model KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials. Written byBree Foster, PhD

First-in-class therapy repairs DNA damage in Alzheimer's model KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials. Written byBree Foster, PhD https://www.drugdiscoverynews.com/first-in-class-therapy-repairs-dna-damage-in-alzheimer-s-model-17317?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_K4Yy8oBUV0TulX8R0XFzqRLzLkskJ_gdcfWtL2oVubsbE07lOyO-kUWHXVvH4J5bDuF216TbRUenSjGzn9PIz2p4CmA&_hsmi=432069604&utm_content=432069604&utm_source=hs_email Alzheimer’s disease (AD) is most commonly associated with the pathological hallmarks of amyloid-beta and tau. However, mounting evidence suggests that damage to the genome, in the form of DNA breaks, may also play an important role in disease progression.